GlaxoSmithKline has made the decision to discontinue manufacturing Ceftin (cefuroxime axetil) Oral Suspension. The product discontinuation is not due to any quality, safety, or efficacy issues. Specifically, the following presentations will no longer be available:
- 125mg/5mL; 100mL bottles (anticipated final date of availability: April 1, 2018)
- 250mg/5mL; 50mL bottles (anticipated final date of availability: January 15, 2018)
- 250mg/5mL; 100mL bottles (anticipated final date of availability: February 15, 2018)
Ceftin is a cephalosporin antibacterial drug indicated for the treatment of the following infections due to susceptible bacteria: pharyngitis/tonsillitis, acute bacterial otitis media, acute bacterial maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, uncomplicated skin and skin structure infections, uncomplicated urinary tract infections, uncomplicated gonorrhea, early Lyme disease, and impetigo.
Ceftin is currently available in a 250mg and 500mg tablet formulation.
For more information visit FDA.gov.